Ethanolamine (Colamine)

Subscribe to Selected New Research on Ethanolamine

314 relevant articles (3 outcomes, 14 trials/studies) found for this Bio-Agent

Description: A viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin. It is used as a surfactant, fluorimetric reagent, and to remove CO2 and H2S from natural gas and other gases.

Also Known As:

Colamine; Monoethanolamine; 2 Aminoethanol; 2-Aminoethanol

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Experts

1.	Ponde, Datta E: 1 article (05/2008)
2.	Mintz, Akiva: 1 article (05/2008)
3.	Wang, Limin: 1 article (05/2008)
4.	Ando, Kosei: 1 article (02/2008)
5.	Heymann, Dominique: 1 article (02/2008)
6.	Mori, Kanji: 1 article (02/2008)
7.	Martelli-Júnior, Hercílio: 1 article (12/2007)
8.	Miranda, Leonardo de Paula: 1 article (12/2007)
9.	Bonan, Paulo Rogério Ferreti: 1 article (12/2007)
10.	Mendes, Danilo Cangussu: 1 article (12/2007)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 02/01/2008 - "Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases." 01/01/2008 - "Analyses of fatty acyl chains from ethanolamine-containing plasmalogens provided a reliable tumor marker that correlated with high Se and linearity with metastases spreading" 03/03/1988 - "Metastases from cells cultured with serum, choline or dimethylethanolamine, but not from monomethylethanolamine or ethanolamine, were extensive and highly invasive" 03/03/1988 - "Serum and choline-fed cells most frequently metastasized (74% and 68%, respectively), while frequency of lung metastasis was 46%, 42% and 17% in mice injected with cells fed with dimethylethanolamine, monomethylethanolamine, and ethanolamine, respectively" 07/01/2006 - "Additional chemotherapy and biotherapy options to reduce tumor burden and prevent metastases include intra-arterial chemotherapy in osteosarcoma; intrapleural chemotherapy, aerosol 9-nitrocamptothecin, or protracted irinotecan and temozolomide in Ewing's sarcoma; continuous hyperthermic peritoneal perfusion for malignancy involving the peritoneum, such as desmoplastic small round cell tumor; and ifosfamide with muramyl tripeptide phosphatidyl ethanolamine liposomes in osteosarcoma" Order ALL the reference details at left...
2.	Autolysis 02/01/1983 - "pneumoniae that were rendered resistant to autolysis by growth in ethanolamine" 01/01/1985 - "Autolysis-resistant type 14 pneumococci were obtained by substituting ethanolamine for choline in a defined culture medium" 01/01/1968 - "Biological consequences of the replacement of choline by ethanolamine in the cell wall of Pneumococcus: chanin formation, loss of transformability, and loss of autolysis." 04/16/1996 - "Phosphatidyl inositol, phosphatidyl choline, phosphatidyl glycerol, phosphatidyl serine, phosphatidyl ethanolamine, phosphatidic acid and sphingomyelin were all found to be effective at reducing the Ca2+ requirement for m-calpain autolysis" Order ALL the reference details at left...
3.	Osteosarcoma (Osteogenic Sarcoma) 06/01/2006 - "Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a synthetic biological investigational agent used for treating osteosarcoma" 02/01/2008 - "Liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) is a new agent that improves overall osteosarcoma survival (chemotherapy without L-MTP-PE 70% versus with L-MTP-PE 78%; p = 0.03)" 02/01/2008 - "Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases." 06/01/2006 - "Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma." 07/01/2006 - "Additional chemotherapy and biotherapy options to reduce tumor burden and prevent metastases include intra-arterial chemotherapy in osteosarcoma; intrapleural chemotherapy, aerosol 9-nitrocamptothecin, or protracted irinotecan and temozolomide in Ewing's sarcoma; continuous hyperthermic peritoneal perfusion for malignancy involving the peritoneum, such as desmoplastic small round cell tumor; and ifosfamide with muramyl tripeptide phosphatidyl ethanolamine liposomes in osteosarcoma" Order ALL the reference details at left...
4.	Esophageal and Gastric Varices (Esophageal Varices) 11/01/1989 - "Efficacy of ethanolamine and polidocanol in the eradication of esophageal varices" 07/01/1994 - "We describe the first patient who had uncomplicated sclerotherapy with ethanolamine for esophageal varices, and on two occasions this patient developed left-sided bloody pleural effusion within 12-72 h after sclerotherapy" 07/01/1990 - "Esophageal varix sclerosis: ethanolamine or polidocanol?]" Order ALL the reference details at left...
5.	Neoplasms (Cancer) 07/01/2008 - "PC was significantly higher (0.39 +/- 0.40 mmol/kg vs. 0.02 +/- 0.07 mmol/kg, z = 3.5), while ethanolamine (Eth) was significantly lower in cancer versus benign prostate tissues (1.0 +/- 0.8 mmol/kg vs. 2.3 +/- 1.9 mmol/kg, z = 3.3)" 01/01/1994 - "We are now presenting the pharmacokinetics, in vivo metabolism and distribution of a [14C]PNAE(s) preparation (1-O-octadecyl-2-oleoyl-sn-glycero-3-phospho-(N-[U-14C]palmitoyl) ethanolamine in the intact or Mc11-tumor-bearing BDF1 mice" 01/01/1993 - "The macrophage activator muramyl tripeptide-phosphatidyl ethanolamine (MTP-PE) was infused in liposomal form in 14 metastatic cancer patients (4 mg i.v. during 30 min twice weekly for 12 weeks)" 09/01/1988 - "Mammary tumor cells which retain properties of the normal tissue are also likely to be ethanolamine responsive, whereas dedifferentiated, highly tumorigenic mammary tumor cells are ethanolamine nonresponsive" 05/01/2008 - "METHODS: We carried out comparison of radiolabeled choline and ethanolamine by cell uptake study using 8 different cancer cell lines" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Choline (Choline Chloride)
2.	Serine (L-Serine)
3.	Phosphatidylinositols (Phosphatidylinositol)
4.	Phosphatidic Acids (Phosphatidic Acid)
5.	polidocanol (Laureth)
6.	Phosphatidylglycerols
7.	m-calpain
8.	Phospholipids
9.	Cytidine Diphosphate Choline (Citicoline)
10.	Phosphatidylcholines (Phosphatidylcholine)

Related Therapies and Procedures

1.	Sclerotherapy
2.	Drug Therapy (Chemotherapy)
3.	Lenses
4.	Neurosurgical Procedures
5.	Resuscitation

Best Treatments:
Research Summary Report
on Neoplasm Metastasis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3049 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>